Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of its CRYOcheck™ Factor VIII Inhibitor Kit in the U.S. This clearance follows approvals received from regulatory authorities in Canada, the European Union, Australia, and New Zealand, where the kit launched in February of this year.
Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck™ Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities last month.
2019 is upon us and we're gearing up for an eventful year. Check out our updated list of conferences. We hope to see you there!
On December 1, Precision BioLogic unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the 60th ASH Annual Meeting in San Diego, CA.
Please note that Precision BioLogic will be closed December 22 to January 1. We will reopen the morning of January 2, 2019.
To avoid potential shipping delays during the holidays, please contact us by December 14 if you will need to order any of our products before the new year.
HALIFAX, November 1, 2018—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the completed acquisition of Affinity Biologicals Inc., a primary manufacturer of reagents and kits used in hemostasis and thrombosis research and diagnostics.
Members of the Precision BioLogic team will be at the following events:
Clinical and Laboratory Update in Thrombosis and Anticoagulation
Oct 31–Nov 2 in Scottsdale, AZ
Nov 1–3 in Halifax, NS
We'd love to see you. If you are attending either of these events, please be sure to drop by our booth and say hello.
The countdown is on! Do you know thrombosis? Learn more at worldthrombosisday.org.
April 22-28 is lab week! Precision BioLogic salutes medical laboratory professionals working behind the scenes, conducting tests that guide more than 70% of medical decisions*. The tests these healthcare detectives conduct save time, costs, and lives by enabling early detection and prevention of disease.
In recognition of World Hemophilia Day on April 17, Precision BioLogic offices were lit up in red.
2018 marks the company's sixth year supporting World Hemophilia Day.
On April 17, 2018, the global bleeding disorders community and the World Federation of Hemophilia (WFH) will come together to promote and encourage Sharing Knowledge and the role it plays in building a stronger community. Precision BioLogic is pleased to support the WFH and World Hemophilia Day.
Precision BioLogic, in collaboration with Roche and Genentech, a member of the Roche Group, unveiled data from the study of a new kit for a modified Nijmegen-Bethesda Assay (MNBA) at the Thrombosis & Hemostasis Societies of North America (THSNA) summit in San Diego, California last week.
Heading to San Diego for THSNA March 8-10? If so, we’d love to see you. Drop by and visit us at booth 115.
And, be sure to check out our live poster presentation, Friday at 5:45–6:30 pm.
Poster 143: Performance of a New Kit for a Modified Nijmegen-Bethesda Assay: Comparison of a Chromogenic Versus a Clot-based Factor VIII Inhibitor Assay in Plasma from Persons with Hemophilia A (PwHA)
Ali Sadeghi-Khomami, Marc Boylan, David C. Chen, Joanne I. Adamkewicz